title: Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.
abstract: TENB2, also known as tomoregulin or transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains, is a transmembrane proteoglycan overexpressed in human prostate tumors. This protein is a promising target for antimitotic monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADC) therapy. Nonlinear pharmacokinetics in normal mice suggested that antigen expression in normal tissues may contribute to targeted mediated disposition. We evaluated a predosing strategy with unconjugated antibody to block ADC uptake in target-expressing tissues in a mouse model while striving to preserve tumor uptake and efficacy.
  
  
  METHODS
  Unconjugated, unlabeled antibody was preadministered to mice bearing the TENB2-expressing human prostate explant model, LuCaP 77, followed by a single administration of (111)In-labeled anti-TENB2-MMAE for biodistribution and SPECT/CT studies. A tumor-growth-inhibition study was conducted to determine the pharmacodynamic consequences of predosing.
  
  
  RESULTS
  Preadministration of anti-TENB2 at 1 mg/kg significantly increased blood exposure of the radiolabeled ADC and reduced intestinal, hepatic, and splenic uptake while not affecting tumor accretion. Similar tumor-to-heart ratios were measured by SPECT/CT at 24 h with and without the predose. Consistent with this, the preadministration of 0.75 mg/kg did not interfere with efficacy in a tumor-growth study dosed at 0.75 mg or 2.5 mg of ADC per kilogram.
  
  
  CONCLUSIONS
  Overall, the potential to mask peripheral, nontumor antigen uptake while preserving tumor uptake and efficacy could ameliorate toxicity and may significantly affect future dosing strategies for ADCs.
authors.affiliation: Genentech Research and Early Development, South San Francisco, California 94080, USA.
authors.forename: C Andrew
authors.initials: CA
authors.lastname: Boswell
authors.forename: Eduardo E
authors.initials: EE
authors.lastname: Mundo
authors.forename: Crystal
authors.initials: C
authors.lastname: Zhang
authors.forename: Shannon L
authors.initials: SL
authors.lastname: Stainton
authors.forename: Shang-Fan
authors.initials: SF
authors.lastname: Yu
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Lacap
authors.forename: Weiguang
authors.initials: W
authors.lastname: Mao
authors.forename: Katherine R
authors.initials: KR
authors.lastname: Kozak
authors.forename: Aimee
authors.initials: A
authors.lastname: Fourie
authors.forename: Paul
authors.initials: P
authors.lastname: Polakis
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Khawli
authors.forename: Kedan
authors.initials: K
authors.lastname: Lin
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology* / Q000378:metabolism* / Q000627:therapeutic use; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D051379:Mice; D064847:Multimodal Imaging; D009363:Neoplasm Proteins / Q000276:immunology*; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D000906:Antibodies; D018796:Immunoconjugates; D007205:Indium Radioisotopes; D008565:Membrane Proteins; D009363:Neoplasm Proteins; C423567:TMEFF2 protein, human